Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Prior to Surgery in HPV-Negative Head and Neck Cancer
NCT07254962Phase 2Not yet recruiting
- Sponsor
- Jewish General Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Jewish General Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07254962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254962.